Christopher Johnson Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Associate Professor
faculty
Pharmacy Practice, College of Pharmacy
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Christopher Johnson's research focuses on the pharmacological management of chronic diseases, particularly inflammatory bowel disease (IBD) and type-2 diabetes with cardiovascular disease. He investigates the efficacy and safety of therapeutic agents, including guselkumab for Crohn's disease and the utilization and costs associated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in managing type-2 diabetes and cardiovascular disease.
His work also extends to understanding factors influencing patient outcomes and healthcare utilization. This includes examining the role of medical and social determinants of health in predicting adverse outcomes for patients with IBD and the impact of outpatient follow-up on hospital readmission rates in this population. Additionally, Johnson has explored the financial burden of cannabinoid hyperemesis syndrome on the healthcare industry.
Prior to his current focus, Johnson's research interests have included the genetic mechanisms of bacterial transport systems in *Enterococcus faecalis*, interactions of mobile genetic elements, and even ecological overlap studies concerning baleen whales and krill fisheries. His scholarship metrics include an h-index of 50, 155 total publications, and 14,110 total citations.
Metrics
- h-index: 50
- Publications: 155
- Citations: 14,110
Selected Publications
-
EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists (2024)
Collaboration Network
Top Collaborators
- Medical and social determinants of health as predictors of adverse outcomes in patients with inflammatory bowel disease
- S820 Medical and Social Determinants of Health as Predictors of Adverse Outcomes in Patients With Inflammatory Bowel Disease
- Medical and social determinants of health as predictors of adverse outcomes in patients with inflammatory bowel disease
- S820 Medical and Social Determinants of Health as Predictors of Adverse Outcomes in Patients With Inflammatory Bowel Disease
- Medical and social determinants of health as predictors of adverse outcomes in patients with inflammatory bowel disease
- S820 Medical and Social Determinants of Health as Predictors of Adverse Outcomes in Patients With Inflammatory Bowel Disease
- Medical and social determinants of health as predictors of adverse outcomes in patients with inflammatory bowel disease
- Close outpatient follow-up associated with reduced readmission rates in patients with inflammatory bowel disease
- Two ABC transport systems carry out peptide uptake in <i>Enterococcus faecalis</i>: Their roles in growth and in uptake of sex pheromones
- Two ABC transport systems carry out peptide uptake in <i>Enterococcus faecalis</i>: Their roles in growth and in uptake of sex pheromones
- Two ABC transport systems carry out peptide uptake in <i>Enterococcus faecalis</i>: Their roles in growth and in uptake of sex pheromones
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry
- S820 Medical and Social Determinants of Health as Predictors of Adverse Outcomes in Patients With Inflammatory Bowel Disease
Similar Researchers
Based on overlapping research topics